Stock Track | Syndax Pharmaceuticals Plunges 8.91% Amid Disclosed Risks to Revenue Growth

Stock Track2025-03-05

Syndax Pharmaceuticals (SNDX) stock plummeted 8.91% in intraday trading on Tuesday, following the company's disclosure of new risks that could impact its revenue growth prospects.

According to the company's filing, Syndax faces challenges in navigating regulatory hurdles and unfavorable market conditions, which could hinder its ability to drive revenue growth. These disclosed risks have introduced uncertainties around the company's future financial performance and growth trajectory, prompting investors to reevaluate the stock's valuation.

While analysts maintain a mixed outlook on the healthcare stock, with an average "buy" rating and a mean price target of $36.29, the disclosed revenue growth challenges appear to have weighed heavily on investor sentiment, leading to the significant stock price decline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1129854279?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-05 01:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129854279","market":"us","top_or_hot":-1,"title":"Stock Track | Syndax Pharmaceuticals Plunges 8.91% Amid Disclosed Risks to Revenue Growth","media":"Stock Track","content":"<p>Syndax Pharmaceuticals (SNDX) stock plummeted 8.91% in intraday trading on Tuesday, following the company's disclosure of new risks that could impact its revenue growth prospects.</p>\n\n<p>According to the company's filing, Syndax faces challenges in navigating regulatory hurdles and unfavorable market conditions, which could hinder its ability to drive revenue growth. These disclosed risks have introduced uncertainties around the company's future financial performance and growth trajectory, prompting investors to reevaluate the stock's valuation.</p>\n\n<p>While analysts maintain a mixed outlook on the healthcare stock, with an average \"buy\" rating and a mean price target of $36.29, the disclosed revenue growth challenges appear to have weighed heavily on investor sentiment, leading to the significant stock price decline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Syndax Pharmaceuticals Plunges 8.91% Amid Disclosed Risks to Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Syndax Pharmaceuticals Plunges 8.91% Amid Disclosed Risks to Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-05 01:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Syndax Pharmaceuticals (SNDX) stock plummeted 8.91% in intraday trading on Tuesday, following the company's disclosure of new risks that could impact its revenue growth prospects.</p>\n\n<p>According to the company's filing, Syndax faces challenges in navigating regulatory hurdles and unfavorable market conditions, which could hinder its ability to drive revenue growth. These disclosed risks have introduced uncertainties around the company's future financial performance and growth trajectory, prompting investors to reevaluate the stock's valuation.</p>\n\n<p>While analysts maintain a mixed outlook on the healthcare stock, with an average \"buy\" rating and a mean price target of $36.29, the disclosed revenue growth challenges appear to have weighed heavily on investor sentiment, leading to the significant stock price decline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNDX","symbol_name":"Syndax Pharmaceuticals, Inc. ","start_time":0,"source_url":"","article_id":"1129854279","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129854279","pubTimestamp":1741111110,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Syndax Pharmaceuticals  stock plummeted 8.91% in intraday trading on Tuesday, following the company's disclosure of new risks that could impact its revenue growth prospects.According to the company's filing, Syndax faces challenges in navigating regulatory hurdles and unfavorable market conditions, which could hinder its ability to drive revenue growth. These disclosed risks have introduced uncertainties around the company's future financial performance and growth trajectory, prompting investors","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNDX":"Syndax Pharmaceuticals, Inc. "},"translate_title":"由于披露收入增长风险，Syndax Pharmaceuticals股价暴跌8.91%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNDX":1},"content_text":"Syndax Pharmaceuticals (SNDX) stock plummeted 8.91% in intraday trading on Tuesday, following the company's disclosure of new risks that could impact its revenue growth prospects.\nAccording to the company's filing, Syndax faces challenges in navigating regulatory hurdles and unfavorable market conditions, which could hinder its ability to drive revenue growth. These disclosed risks have introduced uncertainties around the company's future financial performance and growth trajectory, prompting investors to reevaluate the stock's valuation.\nWhile analysts maintain a mixed outlook on the healthcare stock, with an average \"buy\" rating and a mean price target of $36.29, the disclosed revenue growth challenges appear to have weighed heavily on investor sentiment, leading to the significant stock price decline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1129854279","isCrawlerRequest":true}